Breast Cancer

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville. She is also the Director of the Pathology Residency Training Program, as well as Cytopathology and Breast Pathology Fellowship Training Program. In addition, Dr. Masood is the Medical Director of Shands Jacksonville Breast Health Center. An internationally recognized expert in breast cancer diagnosis and prognosis, Dr. Masood has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research, and education.

Pathology

Amila Orucevic obtained MD degree from Medical School of University of Sarajevo, Bosnia and Herzegovina (1983) and PhD from The University of Western Ontario, London, Ontario, Canada (1996). She is a board certified pathologist for Anatomic and Clinical Pathology by The American Board of Pathology (2002), and board certified pathologist for Anatomic Pathology by The Royal College of Physicians and Surgeons of Canada (2002). Currently, she is Attending/Staff pathologist, Associate Professor, and Director of Research at the Department of Pathology, The University of Tennessee Medical Center, Knoxville, TN, USA. She published 21 papers in reputed peer reviewed journals.

Pathology, Breast Cancer

Colleen Huber is a Naturopathic Medical Doctor in private practice in Tempe, Arizona. She is Co-Founder and Secretary of the American Naturopathic Research Institute/Naturopathic Oncology Research Institute (ANRI / NORI). She is a Fellow of the Naturopathic Oncology Research Institute. She is a credentialed physician at Plaza Healthcare in Scottsdale, AZ, a 179-bed in-patient, sub-acute facility, where she practices up to the full-scope of practice for naturopathic physicians licensed in Arizona. She graduated from Southwest College of Naturopathic Medicine in Tempe. Her academic writing has appeared in The L ancet and other medical journals.

Breast Cancer

Raj Kumar received his PhD degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. His research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, he has also served as Editorial Board Member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers

Lei Huo received her Bachelor of Medicine degree at Beijing Medical University and her PhD in Molecular Biology and Genetics at Northwestern University, Chicago. A practicing breast pathologist in MD Anderson Cancer Center, she is actively involved in clinical and translational research in the field of breast cancer. Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others.

Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others

A Jain has completed his PhD from Agra University, India. He was a visiting scientist at Texas A&M University. Currently he is a Professor at Albany State University, GA and program coordinator for Biotechnology program. He has received research funding from NIH, DOD and USDA. He served as Director, Center for Undergraduate Research and currently he is serving as MARC U*STAR project director. He has published more than 25 papers in reputed journals and has been serving as reviewer for six journals of international repute.

Cancer Research

Jin Cheng has completed his MD and PhD from Beijing Capital Medical University and Paris University XIII in 1986 and 1994, respectively. Following his postdoctoral training at Fox Chase Cancer Center in Philadelphia, he was recruited by Moffitt Cancer Center as an assistant professor in 1997. Currently, he is professor and interim chair of Deportment of Molecular Oncology at Moffitt Cancer Center. He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

Yutaka Tsutsumi graduated from Keio University School of Medicine, Tokyo in 1976, and completed his PhD in 1982. He is the certified pathologist, the certified cytologist and the infection control doctor. He worked for the Department of Pathology, Tokai University School of Medicine, Isehara, Japan for 21 years, and in 2001 he moved as a professor to the Department of Pathology, Fujita Health University School of Medicine, Toyoake, Japan. Dr. Tsutsumi, an oboe player, has published more than 200 English-written papers in varied journals, and released plural single-authored textbooks and web sites in the field of pathology and infectious diseases

Cancer, Pathology

Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books

Research interests: Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases.

Founder of the first Breast Specialty clinic in the Eastern Province of Saudi Arabia 2000 and the Breast Oncology Clinic 2009. Pioneer & Founder of the University of Dammam Scientific Chair for Intraoperative Radiotherapy treatment for breast cancer 2010 rendering the University of Dammam the first institution in the region to acquire such an advanced treatment modality.

Prof. Abdel Hadi has contributed to the field of breast diseases by many publications in both national and international journals

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research is focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. He retired in March 2012 and is a professor emeritus at Chiba University after his retirement. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

Mammalian Cell

Federico Cattin has completed his graduation at the age of 25 in the Udine University, and post-graduate studies in the Surgical Department of the same University. He is engaged in the studies about breast cancer and has attended a scholarship in the European Institute of Oncology (IEO) in Milan, held by Prof. Umberto Veronesi. He has published 13 papers in reputed journals. Nowadays he works in the Sterzing General hospital in South Tyrol, in Italy

Breast cancer

Diptendra K Sarkar is the Chief of the Breast Service and Research Unit at IPGMER, Kolkata, India. He is a Founder member and presently the Honorary Secretary of The Association of Breast Surgeons of India. He has delivered more than 150 lectures and orations in various national and international conferences. He has published more than 30 articles and has contributed as author to two different text books. He is the Associate Editor of Indian Journal of Surgery and Surgical Oncology. He is part of the esteemed Governing Council of Association of Surgeons of India. He is the one of the pioneers of Breast Surgery in Eastern India.

Breast Cancer

2007-present Clinical Associate Professor Department of Obstetrics and Gynecology Stanford University Medical Center Stanford, California 2003-2007 Clinical Assistant Professor Department of Obstetrics and Gynecology Stanford University Medical Center Stanford, California 2000-2003 Assistant Clinical Professor Department of Family and Community Medicine University of California, San Francisco San Francisco, California 1993-1995 Clinical Instructor of Medicine Harbor General Hospital UCLA School of Medicine Division of Endocrinology Torrance, California 1993-1995 Clinical Preceptor Presbyterian Intercommunity Hospital USC Family Practice Residency Program Whittier, California

Endocrinology & Metabolism

Amy Levi is currently the Director of the Interdepartmental Nurse-Midwifery Education Program at the University of California San Francisco. This unique program is situated in both the Schools of Medicine and Nursing, and draws from both disciplines to provide graduate education in midwifery and women’s health to registered nurses. She is a founding member of the Center for Women’s Health and Empowerment for the University of California Global Health Institute, and is the liaison to the Global Health Clinical Scholars Program which provides an introduction to global health for students from each of the four health professional schools at UCSF. Dr. Levi is the Clinical Education Consultant for the Health Workforce Pilot Project in the State of California, a study which is evaluating the training trajectory and clinical outcomes of nurse-midwives, nurse practitioners, and physician assistants providing vacuum aspiration abortion care.

Global women’s health, options in reproductive health care, and health care provider education.

Dr. Elias is focused on clinical breast cancer research and is the director of the clinical breast oncology program. This comprehensive program includes a weekly multi-disciplinary clinic and tumor board, a hereditary clinic, benign breast complaint clinic, a screening and breast imaging program, in addition to daily breast specialty oncology clinics. The sarcoma program includes consult/new patient clinics as well as followups. Dr. Elias is the principal investigator on numerous national and local therapeutic trials and is institution PI for the SWOG grant. He is a member of the SWOG breast committee. He is also the Associate Director of the Cancer Center for clinical sciences and oversees the Clinical Investigations Core.

breast imaging program, clinical breast cancer research

Dr. Stachenfeld is an Associate Fellow at the John B. Pierce Laboratory and an Associate Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. My primary research focus is the impact of reproductive hormones on physiological responses to environmental challenges in women. To this end, my work has emphasized fluid regulatory and cardiovascular responses to exercise and temperature exposure.

Our current studies focus on reproductive hormone effects on blood pressure control, autonomic function and endothelial function.

The research in my laboratory is focused on understanding signaling networks within cells and how these signaling events modulate gene expression and proliferation. Extracellular signals are routed through signaling networks where they can activate multiple pathways, integrate at different levels, and form positive and negative feedback loops. The laboratory uses a combination of computational modeling and experimental biology to gain a systems understanding of the network and how it regulates gene expression and proliferation.

computational modeling to biochemical analysis of signaling events to proteomics using reverse phase high density lysate microarrays

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Mr Ragheed Al-Mufti is Chairman of the West of London Breast Cancer Network. He is also Consultant Breast, Endocrine and Oncological Surgeon at St Mary's Hospital, London, and Honorary Senior Lecturer at Imperial College London School of Medicine (2005 to current). He is a former Consultant in Breast, Endocrine & Oncological Surgery at St Bartholomew's and the Royal London Hospitals (2001 to 2005), and Former Senior Lecturer and Consultant Oncological Surgeon at University College London and Whittington Hospitals (1998 to 2001). Surgical training : Senior Surgical Registrar, Career Surgical Registrar and Surgical Research Registrar, London and North East Thames Region, Bristol & Exeter Surgical SHO Notation. Societies:- Elected Member of the National Executive Committee of BASO (Association of Cancer Surgery) - Member of the Association of Surgeons of Great Britain and Ireland - Member of the Association of Breast Surgeons at BASO - Member of the Thames Cancer Registry Advisory Board - Surgical Tutor of the Royal College of Surgeons of England - Examiner for University of London (Imperial College London and University College London).

Breast and endocrine cancers (surgery)

Parmjit Jat undertook his PhD at the Imperial Cancer Research Fund (now CRUK) and Imperial College London from 1978-1982. This was followed by Postdoctoral research at the MIT Centre for Cancer Research in the laboratory of Dr Philip Sharp. From 1987 to 2003 he was a Group Leader at the UCL Branch of the Ludwig Institute for Cancer Research. Since 2003, he has been a Professor of Molecular Cell Biology at the UCL Institute of Neurology and a member of the MRC Prion Unit.

Breast Cancer biology

Jerzy Gubernator studied Biotechnology at Wroclaw University and then has completed his PhD from the same University, Faculty of Biotechnology. Now He is the Head of Department of Lipids and Liposomes at the Faculty of Biotechnology and the director of Academic Center for Biotechnology of Lipid Aggregates in Wroclaw. His main field of investigation are liposomal drug delivery systems. Hi is also specializing in bi functional active drug loading methods. He has published more than 20 papers concerning liposomes and liposomal technology.

Role of Lipids and Liposomes in Breast cancer

Yutaka Tsutsumi graduated from Keio University School of Medicine, Tokyo in 1976, and completed his PhD in 1982. He is the certified pathologist, the certified cytologist and the infection control doctor. He worked for the Department of Pathology, Tokai University School of Medicine, Isehara, Japan for 21 years, and in 2001 he moved as a professor to the Department of Pathology, Fujita Health University School of Medicine, Toyoake, Japan. Dr. Tsutsumi, an oboe player, has published more than 200 English-written papers in varied journals, and released plural single-authored textbooks and web sites in the field of pathology and infectious diseases

Cancer, Pathology

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research is focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. He retired in March 2012 and is a professor emeritus at Chiba University after his retirement. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

Mammalian Cell

Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books

Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases.

Federico Cattin has completed his graduation at the age of 25 in the Udine University, and post-graduate studies in the Surgical Department of the same University. He is engaged in the studies about breast cancer and has attended a scholarship in the European Institute of Oncology (IEO) in Milan, held by Prof. Umberto Veronesi. He has published 13 papers in reputed journals. Nowadays he works in the Sterzing General hospital in South Tyrol, in Italy

Breast cancer

Dr. Makoto Emoto is the Professor of International University of Health and Welfare in Japan and the Director of Gynecology in Center for Preventive Medicine, Sanno Hospital, Fukuoka, Japan and the former Professor of Fukuoka University Hospital. He received his Ph.D. Degree in 1992 from Fukuoka University Medical School. He was the Research Associate in Department of Obstetrics & Gynecology and Pathology in Cambridge University and St. Edmonds College 2000-2002 and in Cell Biology in Harvard University Medical School 2002. He has authored more than 40 publications in leading journals, especially in Gynecologic Oncology and Ultrasound. He is the Board Certified Fellow of the Japan Society of Gynecologic Oncology, Japan Society of Clinical Oncology, and the Japan Society of Ultrasonics in Medicine.

Gynecologic Oncology, Cancer Stem Cell, Angiogenesis, Ultrasound Imaging, Ultrasound Therapy, Drug Delivery System